Analysis of time to regulatory approval in an exception from informed consent trial in trauma patients

Shannon W. Stephens,Christy R. Carroll-Ledbetter,Sarah Duckert,Tanner W. Coffman,Margaret A. Nelson,Joel Rodgers,Russell L. Griffin,Sarah Grzyb,Amy Suen,Jeremy Casey,Steven R. Sloan,Brahm Goldstein,Jay Richwood,Julia Delfs,Adam J. McClintock,Luke Gelinas,Amanda Higley,Bellal Joseph,John B. Holcomb,Jan O. Jansen
DOI: https://doi.org/10.1097/ta.0000000000004465
2024-10-25
Journal of Trauma and Acute Care Surgery
Abstract:Trauma remains one of the leading causes of death and disability in the United States, and progress in reducing preventable death rates has been limited, in part because of the lack of clinical research during early resuscitative care. 1 In 1996, the US Department of Health and Human Services and the Food and Drug Administration issued guidelines for the conduct of "exception from informed consent" (EFIC) clinical trials. 2 One of the key steps for EFIC research is community consultation and public disclosure (CC/PD), which is a process of consultation between the investigative team and representatives of the communities that are likely to experience the condition, in defined geographic locations.
surgery,critical care medicine
What problem does this paper attempt to address?